Agios Announces Safety Profile Confirmed in Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

Agios Pharmaceuticals, Inc.

today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene. "Glioma, cholangiocarcinoma and chondrosarcomas are all extremely difficult-to-treat diseases with limited therapeutic options," said Howard Burris, M.D., Sarah Cannon Research Institute, an investigator for the study. "Today's Phase 1 dose-escalation data are encouraging, as they confirm a well-tolerated safety profile and show signals of clinical activity that support further evaluation in patients with IDH1